Daclizumab (Zinbryta®)

Assessment Status Rapid review complete
Drug Daclizumab
Brand Zinbryta®
Indication Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.
Assessment Process
Rapid review commissioned 26/09/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations.

7/03/2018 – The European Medicines Agency (EMA) has recommended the immediate suspension and recall of daclizumab.